A Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease

Inclusion Criteria: * Males and females must be ≥ 18 to ≤ 80 years of age at the time of signing the informed consent form (ICF). * Diagnosis of pulmonary hypertension (PH) associated with interstitial lung disease (ILD) (including idiopathic interstitial pneumonia \[IIP\], idiopathic pulmonary fibrosis \[IPF\], connective tissue disease \[CTD\], sarcoidosis). * Male and female participants must use contraceptives that are consistent with local regulations regarding the methods of contraception for those participating in clinical studies. * Male participants: Male participants who are not sterile, with female partners of childbearing potential, must be using effective contraception from Day 1 to at least 90 days after the last dose of study drug. Male participants with women of child bearing potential (WOCBP) partner must use a condom in order to avoid potential exposure to embryo/fetus. \- Female participants: Women must be postmenopausal (defined as no menses for 12 months without an alternative medical cause), surgically sterile, (ie,hysterectomy and/or bilateral salpingo-oophorectomy) or using highly effective contraception methods (ie, methods that alone or in combination achieve \<1% unintended pregnancy rates per year when used consistently and correctly) from Day 1 to at least 90 days after the last dose of study drug. \- Capable of giving signed informed consent that includes compliance with the requirements and restrictions listed in the ICF and in this protoco…